

[Go to Product page](#)

Datasheet for ABIN1713685 **anti-LIMA1 antibody (AA 161-260)**

Overview

Quantity:	100 µL
Target:	LIMA1
Binding Specificity:	AA 161-260
Reactivity:	Human
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This LIMA1 antibody is un-conjugated
Application:	Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunocytochemistry (ICC), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Product Details

Immunogen:	KLH conjugated synthetic peptide derived from human EPLIN
Isotype:	IgG
Predicted Reactivity:	Human, Mouse, Dog, Cow, Sheep, Horse, Rabbit
Purification:	Purified by Protein A.

Target Details

Target:	LIMA1
Alternative Name:	EPLIN (LIMA1 Products)

Target Details

Background: Synonyms: 1110021C24Rik, Epithelial protein lost in neoplasm, Epithelial protein lost in neoplasm beta, EPLIN, FLJ38853, LIM domain and actin binding 1, LIM domain and actin binding protein 1, LIM domain and actin-binding protein 1, LIMA1, LIMA1_HUMAN, MGC131726, SREBP3, Sterol regulatory element binding protein 3.

Background: Epithelial protein lost in neoplasm (EPLIN) is a cytoskeleton-associated protein characterized by the presence of a single centrally located lin-11, isl-1 and mec-3 (LIM) domain. It also contains at least two Actin-binding domains, in which the C-terminal domain binds more effectively than the N-terminal domain. By binding Actin monomers and filaments, EPLIN is involved in regulation of the Actin cytoskeleton by increasing the number and size of Actin stress fibers, delaying filament nucleation, reducing formation of branched filaments and bundling of Actin filaments. It also inhibits membrane ruffling and Actin filament depolymerization. EPLIN is strongly expressed in placenta, kidney, pancreas, prostate, ovary, spleen and heart, and to a lesser degree in lung, liver, brain, skeletal muscle, thymus, testis and intestine. It is expressed as two isoforms, EPLIN- and EPLIN-. Downregulation of EPLIN-expression may contribute to the motility of invasive tumor cells.

Gene ID: 51474

Application Details

Application Notes: WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200
ICC 1:100-500

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 µg/µL

Buffer: 0.01M TBS(pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Preservative: ProClin

Handling

Precaution of Use:	This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
Storage:	4 °C,-20 °C
Storage Comment:	Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
Expiry Date:	12 months